Page 112 - NobleCon19revC2_Neat

Health Care
Date November 21, 2023 Health Care
52wk High $12.50
52wk Low $0.99 Hoth Therapeutics, Inc. HOTH $1.05
1 Rockefeller Plaza
New York, NY 10020

(USD - in millions) www.hoththerapeutics.com
Market Cap 4.7
Enterprise (7.2)
Basic Shares Out. 4.35 COMPANY OVERVIEW
Float 4.31
Institutional Holdings 2.21% Detailed Analysis:Channelchek.com
Short Interest 0.02
Avg. 90-Day Volume 0.21 Hoth Therapeutics Inc is a development stage biopharmaceutical
company. It is focused on targeted therapeutics for patients suffering
from conditions such as atopic dermatitis, also known as eczema. The
company owns the BioLexa Platform which combines an FDA-
EPS Data approved zinc chelator with one or more approved antibiotics in a
topical dosage form to address unchecked eczema flare-ups.
2021 2022 2023
CQ1 (6.00) (2.75) (0.88)
CQ2 (3.50) (2.25) (0.57)

CQ3 (3.50) (2.05) (0.60)
CQ4 (3.50) (2.72) (0.53)
CY (16.00) (9.50) (2.58) Source: Channelchek/QuoteMedia

Long-Term EPS Estimate N/A
Price/Book (mrq) 2.42
ROE (ttm) -100.65
Debt-to-Total Cap. (mrq) N/A
Fiscal Year End 31-Dec
1 Rockefeller PNew York NY 10020

Key Executives
CEO: Knie, Robb
CFO: Briones, David
COO: Springer, Hayley
IR: N/A
Noble Capital Markets, Inc.
Source: Capital IQ, Noble Financial estimates, company filings
Noble Senior Analyst 561-994-1191 noblecapitalmarkets.com
Robert LeBoyer MEMBERS: FINRA, SIPC, MSRB
Following the conference, complete video library of presentations will be
rleboyer@noblelsp.com available at: channelchek.com | nobleconference.com
(212) 896-4625

Refer to the back of the book for disclosures